Sonnet Biotherapeutics Holdings Inc - Asset Resilience Ratio
Sonnet Biotherapeutics Holdings Inc (SONN) has an Asset Resilience Ratio of 0.02% as of March 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Sonnet Biotherapeutics Holdings Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how Sonnet Biotherapeutics Holdings Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Sonnet Biotherapeutics Holdings Inc.
Liquid Assets Composition Over Time
This chart breaks down Sonnet Biotherapeutics Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Sonnet Biotherapeutics Holdings Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.84K | 0.02% |
| Total Liquid Assets | $10.84K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Sonnet Biotherapeutics Holdings Inc maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sonnet Biotherapeutics Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Sonnet Biotherapeutics Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Sonnet Biotherapeutics Holdings Inc (None–None)
The table below shows the annual Asset Resilience Ratio data for Sonnet Biotherapeutics Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Sonnet Biotherapeutics Holdings Inc
As of December 2, 2025, Sonnet BioTherapeutics Holdings, Inc. was acquired by Hyperliquid Strategies Inc, in a reverse merger transaction. Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that bin… Read more